Revenue jumped 49% to $105.8 million on Sanity acquisition.

Key Takeaways; Cannabis Sector Curaleaf Holdings Announced Intention to Launch a Hostile Takeover Bid to Acquire Aurora Cannabis Organigram Posted Record Quarter as Sanity Group Acquisition Fueled Global Expansion Key Takeaways; Psychedelic Sector Optimi Health Set Up US$100 Million Equity Facility to Support Growth Definium Therapeutics’ Phase 3 Trial Delivered Strong Results for DT120 in […]

Moby summary of Organigram Global Inc.'s Q3 2026 earnings call

International expansion drives 49% revenue surge and record profitability, with full-year guidance raised above $350 million.

OrganiGram (OGI) delivered earnings and revenue surprises of -400.00% and +12.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Organigram Global (NASDAQ:OGI) reported record third-quarter fiscal 2026 revenue and adjusted EBITDA, aided by the consolidation of Germany-based Sanity Group and improving performance in several Canadian cannabis categories. Net revenue rose 49% year over year to C$105.8 million, while adjusted EB

OrganiGram Holdings (TSX:OGI) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View the webcast at https://events.q4inc.com/analyst/574618022?pwd=FVnom6fM Summary Organigram Global Inc reported a challenging Q2 with a decline in net revenue to 59.8 million, primarily due to is

OrganiGram Holdings (NASDAQ:OGI) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://events.q4inc.com/analyst/574618022?pwd=FVnom6fM Summary Organigram Global Inc faced challenges in Q2 with Canadian recreational market growth slowing a

Despite a challenging quarter with revenue declines, Organigram Global Inc (OGI) remains optimistic about future growth, driven by strategic acquisitions and market leadership.

Organigram reported weaker second-quarter revenue and profitability as vape and infused pre-roll sales slowed, while the company positioned its Sanity Group acquisition as a major international growth catalyst. Key Investor TakeawaysOrganigram (NASDAQ:OGI) posted a 9% year-over-year decline in both gross revenue and net revenue during fiscal Q2 2026.